{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:05:13Z","timestamp":1781121913015,"version":"3.54.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,10]]},"DOI":"10.7759\/cureus.110621","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:54:08Z","timestamp":1781121248000},"source":"Crossref","is-referenced-by-count":0,"title":["Glucagon-Like Peptide-1 Receptor Agonists Across the Heart Failure Spectrum: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Vicky","family":"Muller Ferreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Ayres Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. J Am Coll Cardiol. 2022, 79:17. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac120","article-title":"Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets","volume":"118","author":"Borlaug BA","year":"2023","unstructured":"Borlaug BA, Jensen MD, Kitzman DW, Lam CS, Obokata M, Rider OJ. Obesity and heart failure with preserved ejection fraction: new insights and pathophysiological targets. Cardiovasc Res. 2023, 118:3434-50. 10.1093\/cvr\/cvac120","journal-title":"Cardiovasc Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker DJ","year":"2018","unstructured":"Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab. 2018, 27:740-56. 10.1016\/j.cmet.2018.03.001","journal-title":"Cell Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/s41569-023-00849-3","article-title":"Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action","volume":"20","author":"Ussher JR","year":"2023","unstructured":"Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023, 20:463-74. 10.1038\/s41569-023-00849-3","journal-title":"Nat Rev Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar N","year":"2021","unstructured":"Sattar N, Lee MMY, Kristensen SL, et al.. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021, 9:653-62. 10.1016\/S2213-8587(21)00203-5","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306963","article-title":"Semaglutide in patients with heart failure with preserved ejection fraction and obesity","volume":"389","author":"Kosiborod MN","year":"2023","unstructured":"Kosiborod MN, Abildstr\u00f8m SZ, Borlaug BA, et al.. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med. 2023, 389:1069-84. 10.1056\/NEJMoa2306963","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes","volume":"390","author":"Kosiborod MN","year":"2024","unstructured":"Kosiborod MN, Petrie MC, Borlaug BA, et al.. Semaglutide in patients with obesity-related heart failure and type 2 diabetes. N Engl J Med. 2024, 390:1394-407. 10.1056\/NEJMoa2313917","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2410027","article-title":"Tirzepatide for heart failure with preserved ejection fraction and obesity","volume":"392","author":"Packer M","year":"2025","unstructured":"Packer M, Zile MR, Kramer CM, et al.. Tirzepatide for heart failure with preserved ejection fraction and obesity. N Engl J Med. 2025, 392:427-37. 10.1056\/NEJMoa2410027","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.10260","article-title":"Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial","volume":"316","author":"Margulies KB","year":"2016","unstructured":"Margulies KB, Hernandez AF, Redfield MM, et al.. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. J Am Med Assoc. 2016, 316:500-8. 10.1001\/jama.2016.10260","journal-title":"J Am Med Assoc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcdd13020103","article-title":"Effect of GLP-1 receptor agonists in heart failure with preserved ejection fraction: a systematic review and meta-analysis","volume":"13","author":"Behers BJ","year":"2026","unstructured":"Behers BJ, Sanchez C, Hozayen O, et al.. Effect of GLP-1 receptor agonists in heart failure with preserved ejection fraction: a systematic review and meta-analysis. J Cardiovasc Dev Dis. 2026, 13:103. 10.3390\/jcdd13020103","journal-title":"J Cardiovasc Dev Dis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2025.156433","article-title":"GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: a systematic review and meta-analysis","volume":"175","author":"Zhang J","year":"2026","unstructured":"Zhang J, Guan X, Kong M, Xia M, Yu Y, Zhang C. GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: a systematic review and meta-analysis. Metabolism. 2026, 175:156433. 10.1016\/j.metabol.2025.156433","journal-title":"Metabolism"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Br Med J. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"Br Med J"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"Br Med J"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1009","article-title":"A refined method for the meta-analysis of controlled clinical trials with binary outcome","volume":"20","author":"Hartung J","year":"2001","unstructured":"Hartung J, Knapp G. A refined method for the meta-analysis of controlled clinical trials with binary outcome. Stat Med. 2001, 20:3875-89. 10.1002\/sim.1009","journal-title":"Stat Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki AA","year":"2016","unstructured":"Veroniki AA, Jackson D, Viechtbauer W, et al.. Methods to estimate the between-study variance and its uncertainty in meta-analysis. Res Synth Methods. 2016, 7:55-79. 10.1002\/jrsm.1164","journal-title":"Res Synth Methods"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins JP","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Br Med J. 2003, 327:557-60. 10.1136\/bmj.327.7414.557","journal-title":"Br Med J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger M","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J. 1997, 315:629-34. 10.1136\/bmj.315.7109.629","journal-title":"Br Med J"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/j.0006-341x.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval S","year":"2000","unstructured":"Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000, 56:455-63. 10.1111\/j.0006-341x.2000.00455.x","journal-title":"Biometrics"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt GH","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch\u00fcnemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. Br Med J. 2008, 336:924-6. 10.1136\/bmj.39489.470347.AD","journal-title":"Br Med J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.657","article-title":"Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial","volume":"19","author":"Jorsal A","year":"2017","unstructured":"Jorsal A, Kistorp C, Holmager P, et al.. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017, 19:69-77. 10.1002\/ejhf.657","journal-title":"Eur J Heart Fail"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2660","article-title":"Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes","volume":"24","author":"Ferreira JP","year":"2022","unstructured":"Ferreira JP, Sharma A, Vasques-N\u00f3voa F, et al.. Albiglutide in patients with type 2 diabetes and heart failure: a post-hoc analysis from Harmony Outcomes. Eur J Heart Fail. 2022, 24:1792-801. 10.1002\/ejhf.2660","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2016.01.008","article-title":"Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction","volume":"4","author":"Lepore JJ","year":"2016","unstructured":"Lepore JJ, Olson E, Demopoulos L, et al.. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC Heart Fail. 2016, 4:559-66. 10.1016\/j.jchf.2016.01.008","journal-title":"JACC Heart Fail"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01498-3","article-title":"Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial","volume":"404","author":"Deanfield J","year":"2024","unstructured":"Deanfield J, Verma S, Scirica BM, et al.. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. Lancet. 2024, 404:773-86. 10.1016\/S0140-6736(24)01498-3","journal-title":"Lancet"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2025.7774","article-title":"Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the  SOUL randomized clinical trial","volume":"186","author":"Pop-Busui R","year":"2026","unstructured":"Pop-Busui R, Rasmussen S, Deanfield JE, et al.. Oral semaglutide and heart failure outcomes in persons with type 2 diabetes: a secondary analysis of the  SOUL randomized clinical trial. JAMA Intern Med. 2026, 186:426-36. 10.1001\/jamainternmed.2025.7774","journal-title":"JAMA Intern Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2024.08.004","article-title":"Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial","volume":"84","author":"Pratley RE","year":"2024","unstructured":"Pratley RE, Tuttle KR, Rossing P, et al.. Effects of semaglutide on heart failure outcomes in diabetes and chronic kidney disease in the FLOW trial. J Am Coll Cardiol. 2024, 84:1615-28. 10.1016\/j.jacc.2024.08.004","journal-title":"J Am Coll Cardiol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3478","article-title":"Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial","volume":"27","author":"Neves JS","year":"2025","unstructured":"Neves JS, Leite AR, Mentz RJ, et al.. Cardiovascular outcomes with exenatide in type 2 diabetes according to ejection fraction: The EXSCEL trial. Eur J Heart Fail. 2025, 27:540-51. 10.1002\/ejhf.3478","journal-title":"Eur J Heart Fail"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.041659","article-title":"Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial","volume":"140","author":"Fudim M","year":"2019","unstructured":"Fudim M, White J, Pagidipati NJ, et al.. Effect of once-weekly exenatide in patients with type 2 diabetes mellitus with and without heart failure and heart failure-related outcomes: insights from the EXSCEL trial. Circulation. 2019, 140:1613-22. 10.1161\/CIRCULATIONAHA.119.041659","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.12.063","article-title":"Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure","volume":"75","author":"Marso SP","year":"2020","unstructured":"Marso SP, Baeres FM, Bain SC, et al.. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol. 2020, 75:1128-41. 10.1016\/j.jacc.2019.12.063","journal-title":"J Am Coll Cardiol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2670","article-title":"Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial","volume":"24","author":"Branch KR","year":"2022","unstructured":"Branch KR, Dagenais GR, Avezum A, et al.. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial. Eur J Heart Fail. 2022, 24:1805-12. 10.1002\/ejhf.2670","journal-title":"Eur J Heart Fail"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/493440-glucagon-like-peptide-1-receptor-agonists-across-the-heart-failure-spectrum-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T19:54:09Z","timestamp":1781121249000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/493440-glucagon-like-peptide-1-receptor-agonists-across-the-heart-failure-spectrum-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":33,"URL":"https:\/\/doi.org\/10.7759\/cureus.110621","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,10]]}}}